Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice

Bodil Bjørndal1*, Eva Katrine Alterås1, Carine Lindquist1,2, Asbjørn Svardal1, Jon Skorve1 and Rolf K. Berge1,2

Abstract

Background: The 4-thia fatty acid tetradecylthiopropionic acid (TTP) is known to inhibit mitochondrial β-oxidation, and can be used as chemically induced hepatic steatosis-model in rodents, while 3-thia fatty acid tetradecylthioacetic acid (TTA) stimulates fatty acid oxidation through activation of peroxisome proliferator activated receptor alpha (PPARα). We wished to determine how these two compounds affected in vivo respiration and mitochondrial efficiency, with an additional goal to elucidate whether mitochondrial function is reflected in plasma acylcarnitine levels.

Methods: C57BL/6 mice were divided in 4 groups of 10 mice and fed a control low-fat diet, low-fat diets with 0.4% (w/w) TTP, 0.4% TTA or a combination of these two fatty acids for three weeks (n = 10). At sacrifice, β-oxidation and oxidative phosphorylation (OXPHOS) capacity was analysed in fresh liver samples. Hepatic mitochondria were studied using transmission electron microscopy. Lipid classes were measured in plasma, heart and liver, acylcarnitines were measured in plasma, and gene expression was measured in liver.

Results: The TTP diet resulted in hepatic lipid accumulation, plasma L-carnitine and acetylcarnitine depletion and elevated palmitoylcarnitine and non-esterified fatty acid levels. No significant lipid accumulation was observed in heart. The TTA supplement resulted in enhanced hepatic β-oxidation, accompanied by an increased level of acetylcarnitine and palmitoylcarnitine in plasma. Analysis of mitochondrial respiration showed that TTP reduced oxidative phosphorylation, while TTA increased the maximum respiratory capacity of the electron transport system. Combined treatment with TTP and TTA resulted in a profound stimulation of genes involved in the PPAR-response and L-carnitine metabolism, and partly prevented triacylglycerol accumulation in the liver concomitant with increased peroxisomal β-oxidation and depletion of plasma acetylcarnitines. Despite an increased number of mitochondria in the liver of TTA + TTP fed mice, the OXPHOS capacity was significantly reduced.

Conclusion: This study indicates that fatty acid β-oxidation directly affects mitochondrial respiratory capacity in liver. As plasma acylcarnitines reflected the reduced mitochondrial β-oxidation in TTP-fed mice, they could be useful tools to monitor mitochondrial function. As mitochondrial dysfunction is a major determinant of metabolic disease, this supports their use as plasma markers of cardiovascular risk in humans. Results however indicate that high PPAR activation obscures the interpretation of plasma acylcarnitine levels.

Keywords: Beta-oxidation, Mitochondrial function, Oxidative phosphorylation, Tetradecylthioacetic acid, Tetradecylthiopropionic acid, Acylcarnitine

* Correspondence: bodil.bjorndal@uib.no
1Department of Clinical Science, University of Bergen, N-5020 Bergen, Norway
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Mitochondrial dysfunction is implicated in the development of many metabolic diseases such as metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), conditions which are highly linked to increased risk of cardiovascular disease (CVD) and myocardial infarction (MI) [1–4]. The mitochondria have several crucial roles in energy metabolism, including the Krebs cycle, ketone body production, ATP production through oxidative phosphorylation of the respiratory chain (OXPHOS), and β-oxidation of fatty acids. Fatty acids (C >14) cannot translocate into the mitochondria, hence they are transported through the carnitine shuttle; Fatty acids are linked to Coenzyme A (fatty acyl-CoA) in the cytosol by acyl-CoA synthetases. Membrane bound carnitine palmitoyltransferase 1 (CPT1) then exchanges CoA with a carnitine molecule, producing fatty acylcarnitine. Acylcarnitine passes the inner mitochondrial membrane into the matrix through a carnitine transporter, where CPT2 exchanges the carnitine molecule with CoA. The acyl-CoA is then ready for β-oxidation. Inhibition of fatty acid β-oxidation is prominent in mitochondrial dysfunction, preventing the removal of excess lipids in the cells, which can result in an increase in toxic intermediate lipid products, including acylcarnitines [5]. In line with this, plasma levels of long-chain acylcarnitines are highly linked to increased mortality in chronic heart failure patients [6]. In obese individuals, overloaded mitochondria will increase the presence of toxic lipid intermediates that can potentially damage the mitochondria, while the removal of excess lipids by increased fat burning is considered beneficial [7]. NAFLD is defined by accumulation of lipids in the liver (mainly in the form of triacylglycerol (TAG)) exceeding 5% per liver weight in the absence of significant alcohol consumption [8]. With a prevalence exceeding 15% in the general population and even higher in people that are overweight, obese or have diabetes, NAFLD is considered one of the most common liver disease in the world [9]. Although it is not an indicator of metabolic syndrome, NAFLD is associated with obesity, insulin resistance and dyslipidemia [10, 11] and can be considered an early predictor of metabolic syndrome [12]. Recently, metabolomics analysis has strongly indicated that defects in lipid regulation are established prior to hyperglycemia and T2DM [13]. Despite its high prevalence, no approved treatments have been defined for NAFLD besides alteration in diet and increased exercise. Treatments targeting mitochondrial function have the potential to ameliorate NAFLD and thus prevent CVD and T2DM.

Artificially generated fatty acid analogues with a sulphur atom included in the carbon chain (thia-fatty acids) are useful tools to investigate the effect of β-oxidation on mitochondrial function and plasma CVD risk factors in animals. Tetradecylthiopropionic acid (TTP), with sulphur in the fourth position from the carboxylic end, has been demonstrated to inhibit mitochondrial β-oxidation [14]. TTP is transported into mitochondria by carnitine palmitoyltransferase 1 and 2 (CPT1 and CPT2), and oxidized to TTAcr-CoA (tetradecylthioacrylic-coenzyme A). This metabolite will accumulate since it is a relatively poor substrate for mitochondrial hydratase and CPT2, resulting in inhibition of CPT2, and thus inhibition of fatty acid oxidation [15]. As a consequence, treatment with TTP increases hepatic TAG levels and induces fatty liver in rats [15–20]. Tetradecylthioacetic acid (TTA), with sulphur in the third position from the carboxylic end, is on the other hand an activator of mitochondrial and peroxisomal β-oxidation [14, 18–21], through its role as a pan-PPAR ligand [19, 22–24]. High-fat fed rats treated with TTA for 50 weeks had lower levels of plasma acylcarnitines compared to control [25]. TTA has also been shown to reduce body weight, adipose tissue depots, and plasma and hepatic TAG levels in rodent studies [26].

In this study, we investigated how hepatic mitochondrial respiration, plasma acylcarnitine levels and lipid levels in plasma, liver and heart were affected by TTP- and TTA-supplemented diets for three weeks in male C57BL/6 mice. The aim was to gain more knowledge on how mitochondrial β-oxidation affects mitochondrial OXPHOS capacity and CVD risk factors. A secondary aim was to use TTP-treatment as a model of chemically induced hepatic steatosis, and investigate whether co-treatment with TTA would prevent TTP-induced hepatic lipid accumulation.

Methods
Animals and diets
The animal study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Norwegian State Board of Biological Experiments with Living Animals (Project no. 5071). Male C57BL/6J BomTac mice, between 8 and 10 weeks old, were purchased from Taconic (Ry, Denmark). Upon arrival, the mice were placed in open cages, two in each cage, and they were allowed to acclimatize to their surroundings for one week before starting the experiment. The mice were kept in a 12 h light/dark cycle at a constant temperature (22 ± 2 °C) and a relative humidity of 55% (± 5%). During the acclimatization period the mice had unrestricted access to chow and tap water. The cages were block-randomized to four different diets, 10 mice per diet, equally distributed between four days of feeding start/sacrifice: Group 1 (control) was given a low-fat diet consisting of 7% (w/w) fat from lard (5% w/w) and soy bean...
oil (2% w/w) purchased from MP Biomedicals (Illkirch France) and Dyet Inc. (Bethlehem, PA, USA) respectively. The feed also contained 19% (w/w), casein and cornstarch, dyetrose, sucrose, fiber, AIN-93-MX mineral mix, AIN-93-VX vitamin mix, L-cysteine, choline bitartrate (Dyets inc.), and tert-Butyl-hydroquinone purchased from Sigma Aldrich [27]. Groups 2–4 were given low-fat diets supplemented with 0.4% (w/w) TTP, 0.4% (w/w) TTA or a combination of 0.4% (w/w) TTP and 0.4% (w/w) TTA. Both TTA and TTP were prepared at the Department of Chemistry, University of Bergen [28]. Mice were fed a fixed amount (9 g dry weight per two mice) daily for 21 days.

At sacrifice, mice were fasted for 4 h, and anaesthetized by inhalation of 2% isoflurane (Schering-Plough, Kent, UK). The abdomen was opened in the midline and EDTA-blood was collected by cardiac puncture and immediately chilled on ice. The samples were centrifuged at −80 °C prior to analysis. Heart, liver, and adipose tissues (epididymal, perirenal, and subcutaneous white adipose tissue depots) were collected and weighed. Fresh samples from each liver was removed for β-oxidation analysis and respiratory analysis, one sample was fixed for transmission electron microscopy (TEM), while the heart and the remaining parts of the liver were immediately snap-frozen in liquid nitrogen and stored at −80 °C until further analysis.

**Quantification of plasma, liver and heart parameters**

Liver and heart lipids were extracted from frozen samples according to Bligh and Dyer [29], evaporated under nitrogen, and redissolved in isopropanol before analysis. Lipids from liver, heart and plasma were measured enzymatically on a Hitachi 917 system (Roche Diagnostics GmbH, Mannheim, Germany) using the cholesterol (Cholesterol CHOD-PAP, 11,491,458–216), and triacylglycerol (Triglycerides GPO-PAP, 11,730,711) kit from Roche Diagnostics, and the free cholesterol (Free Cholesterol FS, Ref 113,609,910,930), non-esterified fatty acid (NEFA FS, Ref 157,819,910,935) and phospholipid kit (Phospholipids FS, Ref 157,419,910,930) from DiaSys (Diagnostic Systems GmbH, Holzheim, Germany). L-carnitine, trimethyl-lysine, γ-butyrobetaine, palmitoylcarnitine and acetylcarnitine were analysed in plasma samples, some pooled from 2 to 3 animals (n = 3–6), by HPLC-MS/MS as described by Vernez et al. [30] with some modifications [31].

**Histology**

Cryo-sections from frozen liver samples were generated using a 1720 Cryostat (Leica Microsystems, Wetzlar, Germany) from 3 to 4 mice per group. The cry-sections were fixed in 4% buffered formalin for 10 min, rinsed 3× in dH2O, and stained in 0.7% (w/v) Oil Red O (Sigma) in propylene glycol for 10 min, rinsed 3× dH2O, and stained with hematoxylin (Thermo Fisher Scientific, Waltham, MA, USA) for 2 min. Finally, sections were rinsed 3× dH2O and mounted with Immumount (Thermo Fisher Scientific). Images were captured using an Olympus BX51 light microscope at 40× magnification with an Olympus DP25 digital colour camera (Olympus Corporation, Tokyo, Japan). Three images per section were captured by a blinded investigator, and representative images were selected.

**Hepatic enzyme activities**

A 250 mg liver sample was chilled on ice and homogenized in 1 mL ice-cold sucrose medium (0.25 M sucrose, 10 mM HEPES, and 1 mM Na4EDTA, adjusted to a pH of 7.4 with KOH). The homogenates were centrifuged at 860 G for 10 min at 4°C and the post-nuclear fraction was removed and used for further analysis. β-oxidation capacity was measured as previously described, using (L-14C) palmitoyl CoA as substrate [32, 33]. The post-nuclear fraction was frozen at −80 °C and later used to measure Acyl-CoA oxidase 1, palmitoyl (ACOX1) activity as described by Madsen et al. [34], with some modifications [35].

**Mitochondrial respiratory capacity**

An 8 mg sample of liver was harvested from 4 to 6 mice per group and kept on ice in cold BIOPS solution for 15–30 min, before homogenization in cold Mir05buffer using a PSI-Shredder HHR-Set (Oroboros Instruments, Innsbruck, Austria). Buffers were made according to http://bioblast.at/index.php/MiPNet03.02_Chemicals-Media. The homogenate was divided between two chambers of an Oroboros Oxygraph-2 k instrument. Samples from 2 animals were run in parallel, using 4 chambers in total per run. The mitochondrial respiratory capacity analysis was carried out according to the substrate-uncoupler-inhibitor titration (SUIT) protocol described by Pesta and Gnaiger [36] with a few changes. Activators and inhibitors were added in the order and concentration given in Table 1. Maximum mitochondrial capacity was measured by stepwise addition of 1 mM carbonyl cyanide p-(trifluoro-methoxy) phenylhydrazone (FCCP), 10 ul per step, until maximum oxygen consumption was achieved.

**Hepatic gene expression**

Total cellular RNA was purified from 20 mg frozen liver samples, and cDNA was produced as described by Vigerust et al. [37]. Real-time PCR was performed with Sarstedt 384-well Multiply-PCR plates (Sarstedt Inc., Newton, NC, USA) on the following genes, using probes and primers from Applied Biosystems (Foster City, CA, USA): acyl-coenzyme A oxidase 1, palmitoyl (Acox1 Mm00499905_m1), gamma-butyrobetaine hydroxylase 1 (Bbox1 Mm01246834_m), CD36 antigen/fatty acid
translocase (Cd36/Fat Mm00432403_m1), carnitine palmitoyltransferase 1a and 2 (Cpt1a Mm01231183_m1 and Cpt2 Mm00487255_m1, respectively), carnitine acetyltransferase (Crat Mm00483985_m1), fatty acid binding protein 1, liver (Fabp1, Mm00444340-m1), NADH dehydrogenase (ubiquinone) Fe-S protein 1 (Ndufs1, Mm00523640_m1), succinate dehydrogenase complex, subunit A, flavoprotein (Sadha, Mm01352366_m1), uncoupling protein 2 (Ucp2, Mm00627599_m1).

Three different reference genes were used; Eukaryotic 18S ribosomal RNA (18S, Kit-FAM-TAMRA (Reference RT-CKFT-18 s) from Eurogentec, Belgium), glyceraldehyde-3-phosphate dehydrogenase (Gapdh, Mm99999915_g1, from Applied Biosystems), Ribosomal protein, large, P0 (Rplp0, Gene ID 111837, from Thermo Fisher Scientific). The optimal normalization gene was determined using Normfinder [38], and data normalized to Rplp0 are presented.

**Transmission electron microscopy**

Fresh liver tissue was cut into approximately 1 mm cubes and fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer at 4 °C for 4–5 days before further processing. After being washed twice in 0.1 M sodium cacodylate buffer on the shaker for 1 h, samples were post fixed for 1 h in 200 μl freshly made osmium tetroxide in 0.1 M sodium cacodylate, washed twice in 0.1 M sodium cacodylate buffer, 5 min each, and dehydrated using increasing ethanol concentration (30% ethanol 10 min, 50% ethanol 15 min, 2 x 70% ethanol). After 1–4 weeks, samples were further dehydrated in 96% ethanol (2 x 10 min) and 100% ethanol (2 x 20 min) before propylene oxide (1,2 epoxy propane) was added and left for approximately 20 min. Epoxy resin was added gradually over a period of about an hour before it was removed. The tubes were filled about half way up with epoxy resin and left for an hour with the caps off to let residue propylene oxide evaporate. Finally, liver samples were added to labelled trays, filled with epoxy resin and left overnight before the epoxy resin was polymerized at 60 °C for 48 h. Samples were sectioned and stained with uranyl acetate and lead citrate by the Molecular Imaging Center at the University of Bergen (www.uib.no/en/rg/mic), and the samples were magnified using Joel JEM-1230 transmission electron microscope (Joel Ltd., Tokyo, Japan). Images of three chosen histological sections of each sample were acquired with a GATAN multiscan camera (Gatan Inc., Pleasanton, CA, USA). The images were captured at a magnification of 5000, 10,000 and 25,000, approximately 3 images per mouse. The image collection was partly blinded as the images of hepatic lipid droplets indicated TTP treatment. The number of mitochondria was estimated from samples from 4 mice.

**Statistical analysis**

Data was analysed using Prism Software (Graph-Pad Software, San Diego, CA) to determine statistical significance. The results are shown as means of 4–10 animals per group with their standard deviations. When possible, normal distribution was determined by the Kolmogorov-Smirnov test (with Dallal-Wilkinson-Lilliefor P value). One-way ANOVA with Dunnet’s post hoc test was used to evaluate statistical differences between groups. P-values < 0.05 were considered statistically significant.

**Results**

**Effect on body, adipose tissue and liver weights**

C57BL/6 mice were fed low-fat diets containing 0.4% (w/w) TTP, 0.4% (w/w) TTA, or a combination of the two thia-fatty acid analogues for 3 weeks. The body weight was lower in both groups fed TTP (Fig. 1a) accompanied with a significant reduction of white adipose tissue mass i.e. epididymal and perirenal fat depots (data not shown), as well as the percentage adipose tissue:body weight (Fig. 1b and c). The subcutaneous fat pat indexes were not affected by any of the diets (Fig. 1d). It was of interest to note that TTA also reduced the epididymal and perirenal adipose index without changing the body weight. The daily feed intake in week 2 and 3 was not changed by the thia fatty acid analogues, although TTP-fed mice demonstrated a lower the feed intake in week 1 (Fig. 1e). In the TTA and TTP + TTA group the percentage liver:body weight was significantly increased compared to control (Fig. 1f).
Hepatic fatty acid oxidation and plasma carnitine esters
The β-oxidation of palmitoyl-CoA was measured in vitro in fresh liver homogenates, and demonstrated an increased fatty acid catabolism in TTA-fed mice (Fig. 2a). This was accompanied by increased plasma levels of acetylcarnitine, an end product of mitochondrial fatty acid oxidation (Fig. 2b). Moreover, the TTA administration significantly increased the hepatic gene expression of Crat, encoding a mitochondrial matrix enzyme carnitine acetyltransferase that transfers short acyl groups from acyl-CoA to L-carnitine, thus regulating the acyl-CoA/CoA ratio of the cells (Fig. 2c). TTP is reported to inhibit the mitochondrial fatty acid oxidation [14]. In this experiment TTP tended to reduce the in vitro palmitoyl-CoA oxidation, but the data were not significant at \( p < 0.05 \). However, the plasma acetylcarnitine level was significantly reduced by TTP treatment while the gene expression of Crat was unchanged (Fig. 2b,c). Interestingly, in liver homogenates from mice treated with both TTA and TTP, in vitro palmitoyl-CoA oxidation was highly increased and the gene expression of Crat upregulated whereas the plasma level of acetylcarnitine was decreased (Fig. 2a-c).

As TTP specifically inhibits mitochondrial β-oxidation at the CPT2-step [15], we wished to determine the contribution from peroxisomal β-oxidation. Hepatic ACOX1 activity was significantly increased in both TTP and TTA-fed mice, and a synergistic effect was observed in co-treated mice (Fig. 2d). The gene expression of Acox1 in liver was increased in the TTA and TTP + TTA group (Fig. 2e). The gene expression of Cpt1a and 2 were significantly increased by TTP + TTA, and Cpt1a was significantly increased by TTP (Fig. 2f,g). Another PPAR-response gene, Hmgs2, the mitochondrial enzyme in ketone body production, was significantly increased in liver by all three interventions (Fig. 2h). There were no significant differences in the gene expression of fatty acid binding protein (Fabp1) in liver (data not shown). However, there was a significant increase in the gene expression of Cd36 in all treatment groups, and results indicate a synergistic effect on the uptake of free fatty acids in the co-treatment group (Fig. 2i).

As mentioned above, long-chain fatty acids have to be esterified to L-carnitine to be transported in and out of the mitochondria. Plasma levels of unesterified L-carnitine were significantly reduced by TTP and TTP
TTA (8.2-fold and 4.7-fold reduction, respectively) (Fig. 3a). In addition, the direct carnitine precursor γ-butyrobetaine was reduced, while trimethyllysine was unaffected by TTP (Fig. 3b,c). TTA on the other hand increased the L-carnitine plasma level compared to control without affecting its precursors. This was linked to an increase in the gene expression of Bbox1, responsible for the generation of L-carnitine from γ-butyrobetaine (Fig. 3d). A synergistic increase in Bbox1 expression was observed in the TTP + TTA-group, despite the decrease in free L-carnitine in this group. In contrast, the 16-carbon chain palmitoylcarnitine was elevated in plasma by TTP and TTA, but only insignificantly by TTP + TTA (Fig. 3e). Propionylcarnitine and iso- /valerylcarnitine, products of branched chain and amino acid degradation, were also reduced by TTP and TTP + TTA (Fig. 3f,g). Octanoylcarnitine, an intermediate product of β-oxidation, was not increased by any of the diets (data not shown).

**Influence of TTP and TTA on tissue lipid levels**

Although in vitro β-oxidation was not significantly reduced by TTP, a 7.3 fold increase in hepatic TAG was observed compared to control (Fig. 4a). Hepatic cholesterol was also increased, while phospholipids were unchanged, resulting in a 2.8-fold increase in total lipids in
liver by TTP (Fig. 4b-d). TTA did not affect liver lipid levels, with the exception of a small, but significant increase in phospholipids. The accumulation of TAG and total liver lipids in the TTP + TTA co-treated mice tended to be of less magnitude than in mice fed TTP alone (1.7-fold and 2.2-fold increase compared to control, respectively). A weak but significant negative correlation was observed between in vitro palmitoyl-CoA oxidation in liver homogenates and hepatic TAG concentration in the control, TTP and TTA group (Fig. 4e, r = -0.460, p = 0.031). In contrast to findings in liver, TAG levels in heart tissue were not significantly affected by thia-fatty acid diets (Fig. 4f). The size of liver lipid droplets was greatly enhanced in TTP-treated mice compared to control (Fig. 4g). TTA and TTP co-treatment was able to reduce the size of lipid droplets

![Fig. 3](image-url) Plasma L-carnitine, carnitine precursors and acylcarnitines in male C57/BL6 mice fed 0.4% (w/w) TTP, 0.4% (w/w) TTA, or TTP + TTA for 3 weeks. a L-carnitine, b trimethyllysine, c β-butyrobetaine, d hepatic Bbox1 gene expression (n = 8), e palmitoyl carnitine, f propionyl carnitine, and g iso-L-valerylcarnitine. Values are means with standard deviations (n = 3–6, unless otherwise stated). Significant difference from controls was determined using one-way ANOVA with Dunnett’s post hoc test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001)

![Fig. 4](image-url) Tissue lipid levels in male C57/BL6 mice fed 0.4% (w/w) TTP, 0.4% (w/w) TTA, or TTP + TTA for 3 weeks. a Hepatic triacylglycerol (TAG), b hepatic cholesterol, c hepatic phospholipids, d total hepatic lipids, e linear regression of liver TAG and β-oxidation of palmitoyl-coenzyme A (n = 18, black circles - control, light gray circles - TTP, grey circles - TTA), f heart TAG (n = 5). Values are means with standard deviations (n = 8, unless otherwise stated). Significant difference from controls was determined using one-way ANOVA with Dunnett’s post hoc test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). g Representative images of liver cryo-sections stained with Oil Red O and captured at 40x magnification using a light microscope (n = 3–4). The black line indicates 100 µm
compared to TTP alone, but they remained larger than in livers of control- and TTA-treated animals.

**Influence of TTP and TTA on plasma lipids**

The efficiency of mitochondrial β-oxidation can strongly influence plasma parameters linked to risk evaluation in CVD. In this study, despite their opposite effect on mitochondrial β-oxidation, both TTP and TTA led to a reduction of plasma TAG levels and phospholipid levels (Table 2). Each thia-fatty acid alone did not influence plasma total cholesterol. However, the co-treatment increased total cholesterol. Strikingly, TTP increased plasma non-esterified fatty acids compared to control, and this was not seen in TTP + TTA-fed mice.

**Mitochondrial morphology and respiration in liver**

The effect of TTP and TTA treatment on mitochondria was further investigated by transmission electron microscopy (TEM) on liver samples. Representative images are shown in Fig. 5a, demonstrating the typical lipid droplets in TTP-treated mice. The average number of mitochondria was estimated from TEM images, and the level was significantly increased in livers from TTP + TTA treated mice (Fig. 5b).

Upon sacrifice, fresh liver samples were harvested and used to determine oxidative phosphorylation (OXPHOS), based on oxygen consumption after addition of octanoyl-carnitine and activators of complex I (CI) and II of the respiratory chain in the presence of ADP. Maximum OXPHOS capacity in uncoupled mitochondria was also determined by adding FCCP. TTA increased the maximum capacity compared to control, while TTP + TTA reduced OXPHOS at both CI + ETF and CI + CII + ETF (Fig. 5c). Adjusting results for the number of mitochondria in each treatment group revealed that TTP + TTA treatment strongly reduced OXPHOS at CI + electron transferring flavoprotein (ETS) (Fig. 5d), although no change was observed in the expression of one of the complex I genes, Ndufs (Fig. 5e). Both TTP alone and TTP + TTA treatment reduced OXPHOS at CI + CII + ETF compared to control (Fig. 5d), while no significant change was observed in the expression of the complex II gene Sdha (Fig. 5f). TTP + TTA significantly reduced maximal capacity in uncoupled mitochondria, and also reduced the maximal capacity when CI was inhibited by rotenone. This was accompanied by a significant increase in the gene expression of uncoupling protein 2 (Ucp2), a gene that has been implicated in the oxidative stress response [39] (Fig. 5g). In contrast, TTA stimulated maximum OXPHOS capacity compared to control (Fig. 5c), without a significant effect on Ucp2 expression (Fig. 5f).

**Discussion**

The rapid removal of TAG and NEFAs from circulation, through both β-oxidation of fatty acids for energy production and storage in adipose tissue, is important to prevent metabolic disease and the development of NAFLD. In this study, we analysed how reduction and storage in adipose tissue, is important to prevent metabolic disease and the development of NAFLD. We also investigated whether co-treatment with TTA could prevent the negative effects of TTP.

The analogues metabolism is grossly similar to the endogenous fatty acids and they are activated to CoA esters. However, while TTA is blocked for β-oxidation, TTP is oxidized to TTAcr-CoA which is an inhibitor of CPT2. We found elevated TAG levels (Fig. 4a), Oil Red O-stained and TEM-images indicated a distinct accumulation of lipid droplets in the liver of TTP-fed mice (Figs. 4g and 5a), and this was accompanied by decreased plasma acetylacetaniline levels (Fig. 2b). This is in line with a pilot study in rats, where 14 days of TTP treatment gave lipid droplet accumulation in a dose-dependent manner, as seen by Oil Red O staining [40]. This suggests reduced hepatic β-oxidation capacity even though the in vitro catabolism of palmitoyl-CoA in liver homogenates only tended to be reduced compared to control (Fig. 2a). In contrast, peroxisomal β-oxidation was increased by TTP at the enzyme activity level. This increase indicates a specific inhibitory effect of TTP on mitochondrial β-oxidation, in agreement with results from previous studies in rats [15, 41, 42].

The hepatic gene expression of the carnitine transferase Cpt1a was highly increased by TTP, and this could indicate a compensatory effect to inhibited CPT2 activity. In addition, TTP increased expression of the PPARα genes Cd36 and Hmgcs2, involved in fatty acid import and keton body production, respectively. This agrees with in vitro assays, which have demonstrated that both

---

**Table 2 Plasma lipid classes in mice treated for 3 weeks with a control low-fat diet, or low-fat diets supplemented with 0.4% (w/w) TTP, TTA or TTP + TTA**

| Plasma levels (mmol/L) | Diet groups | Control | TTP | TTA | TTP + TTA |
|------------------------|-------------|---------|-----|-----|----------|
| TAG                    |             | 1.29 ± 0.28 | 0.54 ± 0.27*** | 0.66 ± 0.22*** | 0.34 ± 0.11** |
| Total cholesterol      |             | 3.70 ± 0.38 | 3.39 ± 0.19 | 3.81 ± 0.25 | 4.16 ± 0.50* |
| Phospholipids          |             | 3.53 ± 0.26 | 2.84 ± 0.24*** | 3.15 ± 0.30* | 2.97 ± 0.33** |
| NEFA                   |             | 0.17 ± 0.05 | 0.31 ± 0.18* | 0.11 ± 0.05 | 0.17 ± 0.06 |

*Values are means with standard deviation (n = 3–6). Values statistically different from control were determined by one-way ANOVA with Dunnett’s post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001

Abbreviations: NEFA Non-esterified fatty acids, TAG Triacylglycerol, TTA Tetradecylthioacetic acid, TTP Tetradecylthiopropionic acid
TTP and TTA are ligands for PPARα, although with different potencies [43]. As expected, TTA treatment significantly increased both mitochondrial and peroxisomal β-oxidation, seen by both enzyme activities and gene expression of Acox1 (Fig. 2). Also, the liver index increased in TTA-treated mice, a known response to PPARα agonists in rodents. Interestingly, a synergistic effect on enzyme activity and expression of a number of PPARα genes, including Acox1, was observed in livers from TTP + TTA-treated mice. Thus, the PPARα effect on ACOX1 activity by TTA seemed to be potentiated by TTP co-treatment. It is possible that the increase in in vitro palmitoyl-CoA β-oxidation observed in the TTP + TTA treated mice could partly be due to peroxisomal β-oxidation, and that this effect was sufficient to lower hepatic lipid accumulation and lipid droplet size (Figs. 2 and 4). Mitochondrial β-oxidation may still have been partly blocked as plasma acetylcarnitine, reflecting the end product of mitochondrial β-oxidation, acetyl-CoA, was strongly reduced both in TTP and TTP + TTA treated mice. In support of this, a significant negative correlation between in vitro fatty acid oxidation of palmitoyl-CoA and hepatic TAG concentration was observed, but only in control, TTA and TTP animals. The
possibility that the active TTP-metabolite (TTAcr-CoA) could have been diluted in the β-oxidation assay should also be considered, thus the inhibitory effect in the presence of TTP may have been stronger in vivo.

Interestingly, despite similar tendencies, the liver was more affected than heart by TTP-induced lipid accumulation (Fig. 4), although mitochondrial fatty acid oxidation is important in both tissues. This sensitivity of the liver towards lipid accumulation may explain the early manifestation of NAFLD during the metabolic syndrome, and our study shows that reduced mitochondrial β-oxidation capacity for 3 weeks strongly induced hepatic lipid accumulation. Similar to findings in rats [40], this did not lead to an increase in liver weight, and it is likely that a longer treatment period is necessary to obtain this NAFLD-symptom.

Visceral adipose tissue depots decreased in all analogue-treatment groups compared to control. Our results indicate that both analogues affect the distribution of body fat by mechanisms that yet have to be identified. Similar mechanisms may also be responsible for the decrease in plasma TAG by both analogues. In TTP-fed mice an increase in plasma NEFA was observed, suggesting an increased lipase-activity in the visceral adipose tissues of these animals (Table 2). The hepatic gene expression of Cds36 was significantly increased by all three interventions, indicating a stimulation of fatty acid uptake from plasma. This suggests that both TTP and TTA can increase mobilization of fatty acids but only TTA-treated animals can efficiently metabolize these fatty acids. This effect probably added to the TTP-induced lipid accumulation in liver. TTA treatment has previously been shown to reduce lipid depots, plasma TAG and NEFA levels, and liver TAG levels through stimulated lipid catabolism in rats [22]. However, in this study liver TAG was unchanged, either due to the short treatment period or the relatively low dose of TTA utilized.

In line with a proposed block in transport of acylcarnitines across the mitochondrial membrane by TTP [15], the observed strong depletion of plasma carnitine may reflect accumulation of long-chain acylcarnitine species in the tissues off TTP-fed animals as well as TTP + TTA-fed animals. Unfortunately, we were not able to analyse acylcarnitine levels in tissues to verify this, but palmitoylcarnitine increased dramatically in plasma (Fig. 4). As mentioned above, plasma acetyl carnitine levels were almost abolished by TTP, in agreement with a block in mitochondrial β-oxidation, and thus reduced production of acetyl-CoA. It is interesting that also products of branched chain fatty acids and amino acid degradation, iso-β-/valerylcarnitine and propionylcarnitine, was strongly reduced by TTP, but this could be secondary to a depletion of free carnitine in these animals. Overall, this supports the use of elevated plasma long-chained acylcarnitines as an indicator of impaired mitochondrial function, and in agreement with this, high levels of palmitoylcarnitine is linked to increased risk of myocardial infarction and death in patients with chronic heart failure [6, 44].

We also show that stimulating β-oxidation with TTA increased plasma acetyl carnitine levels, probably as a result of increased acetyl-CoA production. This indicated that the Krebs cycle and ketone body production was not able to remove the surplus acetyl-CoA generated in livers of TTA-mice, despite a stimulation of Hmgcs2 gene expression (Fig. 2). Surprisingly, plasma palmitoylcarnitine was also increased by TTA compared to control. This increase could be influenced by TTA-carnitine formation, as it was impossible to separate the TTA-carnitine peak from the palmitoylcarnitine peak (data to be published). In long-term TTA-studies with a similar TTA dose, however, the palmitoylcarnitine level was unchanged [25]. We cannot exclude that the observed increase in palmitoylcarnitine was influenced by a stimulated recruitment of fatty acids for catabolism during three weeks of TTA-treatment. In support of this, both TTA and PPARα agonists have previously been shown to increase the gene expression of Bbox1 involved in carnitine biosynthesis [25, 45, 46], and Bbox1 expression as well as L-carnitine was significantly increased by TTA in the current study as well as in long term studies [25]. In the TTP + TTA group, palmitoylcarnitine was insignificantly increased (Fig. 3). As palmitoyl-CoA is a substrate for ACOX1 as well as mitochondrial β-oxidation, stimulated peroxisomal activity may have partly prevented palmitoylcarnitine accumulation in plasma in these mice compared to TTP alone. Altogether, strong PPARα-agonists may complicate the use of plasma acylcarnitines to monitor mitochondrial function.

The increase in both peroxisomal β-oxidation (Fig. 2a) and number of mitochondria (Fig. 5a-b) strongly indicate that TTP and TTA co-treatment had synergetic effects on peroxisomal and mitochondrial proliferation in liver. The number of mitochondria was not significantly affected by TTA alone at this dose. The increased phospholipid level in the TTA and TTP + TTA group also supports peroxisomal proliferation, by reflecting an increase in intracellular membrane structures. In rodents, PPARα-induced peroxisome proliferation is linked to hepatic hypertrophy and hyperplasemia, resulting in increasing liver size independent of lipid accumulation [47], as seen in the TTA- and TTP + TTA treated groups in the current study. However, the observed higher number of mitochondria in livers of TTP + TTA-treated mice did not result in elevated OXPHOS capacity with octanoylcarnitine as substrate (Fig. 5). While TTA stimulated maximal respiration capacity after addition of the uncoupler FCCP, mostly due to activity at CI (Fig. 5c), TTP
+ TTA reduced OXPHOS (CI, CII and ETF) as well as maximum capacity, and increased gene expression of Ucp2, an indicator of increased oxidative stress [39]. Thus, we observed an increased mitochondrial proliferation in the co-treated animals, perhaps due to a synergistic effect on PPARα gene activation, but the mitochondria were most likely not efficient with regard to respiration and ATP-production. TTP treatment significantly reduced hepatic OXPHOS at complex I + II + ETF (Fig. 5c), indicating a link between inhibition of β-oxidation and respiration. This is in line with a recent publication demonstrating a physical connection between enzymes involved in mitochondrial fatty acid β-oxidation and OXPHOS complexes [48]. TTP did, however, not reduce the maximum capacity of oxygen consumption in uncoupled mitochondria.

Thus, the two analogues that have been studied show some similarities as activators of PPAR regulated gene expression. However, differences in their catabolism result in opposite effects on mitochondrial fatty acid oxidation and energy production, which partly modify their PPAR-dependent metabolic effects (summarized in Additional file 1: Table S1).

TTA has previously been shown to have a stronger effect on the expression of genes involved in β-oxidation in liver compared to muscle, heart and adipose tissue [26, 49, 50]. It is, however, likely that the influence of TTP and TTA on other major metabolic organs will contribute to the plasma pool of acylcarnitines, and this should be further studied. Interestingly, particularly the long and medium-chained acylcarnitines have been linked to cardiovascular risk [6, 44]. Although long-chain acylcarnitines were not increased in young individuals with obesity and type 2 diabetes [51], this phenotype is believed to be a consequence of prolonged obesity in adults [52]. In line with this, patients suffering from NASH have significantly higher levels of long-chained acylcarnitines, while they have reduced levels of short-chained acylcarnitines [53]. Our study support that this could be a result of suboptimal mitochondrial function, as inhibition of mitochondrial β-oxidation by TTP was linked to similar changes in plasma palmitoylcarnitine and acetylcarnitine.

Conclusions
This study demonstrate how different thia-fatty acid analogues may be used to investigate disturbances in lipid metabolism and mitochondrial function related to the metabolic syndrome. TAG accumulation was accompanied by reduced OXPHOS activity in livers of TTP-treated mice, while TTA increased hepatic β-oxidation and respiratory capacity, suggesting a direct link between β-oxidation and mitochondrial respiratory efficiency in mice. Combined TTP and TTA treatment increase in vitro β-oxidation and reduced lipid accumulation in liver compared to TTP alone, indicating that TTA can prevent the establishment of fatty liver. However, hepatic OXPHOS capacity was lowered, suggesting dysfunctional mitochondria. Although the co-treatment with TTA was unable to rescue TTP-induced mitochondrial function in this mouse model, TTA treatment has a clear potential to improve mitochondrial function in natural situations of metabolic disease.

The study shows that plasma acylcarnitines, new markers of MI-risk in human CVD patients, reflected the reduced mitochondrial β-oxidation in TTP-fed mice, indicating that they could be useful tools to monitor mitochondrial function. The study however demonstrates that plasma acylcarnitine levels should be interpreted with caution in the presence of PPAR agonists that influence carnitine biosynthesis and turnover.

Additional file

**Additional file 1: Table S1.** Overview of results. (DOCX 101 kb)

**Abbreviations**

ACOX1: Acyl-CoA oxidase 1, palmitoyl; Bbox1: Beta-box protein; CDS1: CDS1 antigen; CD36: CD36 antigen; CD68: CD68 antigen; CPT1: Carnitine palmitoyltransferase 1; CPT2: Carnitine palmitoyltransferase 2; CoA: Coenzyme A; CDI: Complex I; CI: Complex II; CoA: Coenzyme A; CPT1: Carnitine palmitoyltransferase 1; CPT2: Carnitine palmitoyltransferase 2; Covid: Competitor deacetylase transferase; CVD: Cardiovascular disease; Fabp1: Fatty acid binding protein 1; Liver; M: Myocardial infarction; Nahl: Non-alcoholic fatty liver disease; Ndh1: NADH dehydrogenase (ubiquinone) Fe-S protein 1; OXPHOS: Oxidative phosphorylation; PPAR: Peroxisome proliferator activated receptor alpha; Sdha: Succinate dehydrogenase complex, subunit A, flavoprotein; T2DM: Type 2 diabetes mellitus; TAG: Triacylglycerol; TEM: Transmission electron microscopy; TTA: Tetradecylthioacetic acid; TTAcrCoA: Tetradecylthioacrylic acid; TTAcr: Tetradecylthioacrylic-coenzyme A; TTP: Tetradecylthiopropionic acid; Ucp2: Uncoupling protein 2.

**Acknowledgements**

The authors would like to thank Tonunn Eide, Kari Williams, Kari Mortensen, Liv Kristine Øysæd, Svein Krüger and Randi Sandvik for excellent technical assistance. We also thank the master students Tra-My Le and Ancy Wilfred, and the staff at the UIB animal facility.

**Funding**

The study was funded by grant to BB and RKB from Bergen Research Foundation. The founding body did not have a role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

BB, JS, and RKB conceived and planned the study. EKA and BB performed the animal study, electron microscopy, and respiration analysis. EKA and CL performed the real-time PCR analysis. AS performed the acylcarnitine analysis. EKA, BB, and CL analysed the data. BB wrote the manuscript. All authors gave input to the manuscript, and read and approved the final version.

**Ethics approval**

The animal study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Norwegian State Board of Biological Experiments with Living Animals (Project no. 5071).
References

1. Grattagliano I, de Bari O, Bernardi TC, Oliveira PJ, Wang DQ, Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease—from origin to propagation. Clin Pharmacol 2012;45:610–8.

2. Serviddio G, Bellanti F, Vendemiale G, Altermare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2011;5:233–44.

3. Tesser P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2009;19:291–302.

4. Ren J, Pulakat L, Whaley-Connell A, Sowers JR. Mitochondriome: the metabolic syndrome and cardiovascular disease. J Mol Med (Berl). 2010; 88:993–1001.

5. Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet. 2012;51:153–72.

6. Ueland T, Svardal A, Die E, Askvedøl ET, Nymoen SH, Bjornstad B, et al. Disturbed carnitine regulation in chronic heart failure—increased plasma levels of palmitoyl-carnitine are associated with poor prognosis. Int J Cardiol. 2013;167:1892–9.

7. Legrand-Poels S, Esier N, Lhomme L, Scheen A, Paquot N, Piette J. Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. Biochim Pharmacol. 2014;92:131–41.

8. Byrne CD. Fatty liver: role of inflammation and fatty acid nutrition. Prostaglandins Leukot Essent Fatty Acids. 2010;82:265–71.

9. Mavrogiannaki AN, Migdalis IN. Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease newer data. Int J Endocrinol. 2013;2013:450639.

10. Yan E, Durazo F, Song M, Hong K. Nonalcoholic fatty liver disease: pathogenesis, identification, progression, and management. Nutr Rev. 2007;65:376–84.

11. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 2012;36:815–23.

12. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Fish oil and the pan-PPAR agonist tetracyclic fatty acid acid affect the amino acid and carnitine metabolism in rats. PLoS One. 2013;8:e66926.

13. Wenasaj AJ, Rustan AC, Roling-Andersen MH, Caesar R, Jensen K, Kaalhus O, et al. Dietary supplementation of tetracyclic fatty acid acid increases feed intake but reduces body weight gain and adipose depot sizes in rats fed on high-fat diets. Diabetes Obes Metab. 2009;11:1034–49.

14. Ramvsk M, Bjornstad B, Bruheim I, Bohov P, Berge RK. A Phospholipid-protein complex from krill with Antioxidative and Immunomodulating properties reduced plasma Triacylglycerol and hepatic Lipogenesis in rats. Mar Drugs. 2013;11:4375–97.

15. Spytdevol O, Bremer J. Induction of peroxisomal beta-oxidation in 7800 C1 Morris hepatoma cells in steady state by fatty acids and fatty acid analogues. Biochim Biophys Acta. 1989;1003:72–9.

16. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–7.

17. Venero L, Wink M, Krahenbuhl S. Determination of carnitine and acylcarnitines in plasma by high-performance liquid chromatography/ electrospray ionization ion trap tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18:1233–8.

18. Vigerust NF, Bjorndal B, Seifert R, Nygard O, Svardal A, et al. Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. Fertil Steril. 2012;98:1620–6; e1621.

19. Berge RK, Tronstad KJ, Berge K, Kast TH, Wegedahl H, Gudbrandsen OA, et al. The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie. 2005;87:15–20.

20. Kryvi H, Aarland A, Berge RK. Morphologic effects of sulfur-substituted fatty acids on rat hepatocytes with special reference to proliferation of peroxisomes and mitochondria. J Struct Biol. 1990;103:25–65.

21. Toutallia G, Ledsen L, Klemensen B, Vaagenes H, Kryvi H, Froyland L, et al. Proliferation of mitochondria and gene expression of carnitine palmitoyltransferase and fatty acyl-CoA oxidase in rat skeletal muscle, heart and liver by hypolipidemic fatty acids. Biol Cell. 2000;92:317–29.

22. Bjornstad B, Brattelid T, Strand E, Vigerust NF, Svingen GF, Svardal A, et al. Fish oil and the pan-PPAR agonist tetracyclic fatty acid acid affect the amino acid and carnitine metabolism in rats. PLoS One. 2013;8:e66926.

23. Wenasaj AJ, Rustan AC, Roling-Andersen MH, Caesar R, Jensen K, Kaalhus O, et al. Dietary supplementation of tetracyclic fatty acid acid increases feed intake but reduces body weight gain and adipose depot sizes in rats fed on high-fat diets. Diabetes Obes Metab. 2009;11:1034–49.
39. Pi J, Bai Y, Daniel KW, Liu D, Lyght O, Edelstein D, et al. Persistent oxidative stress due to absence of uncoupling protein 2 associated with impaired pancreatic beta-cell function. Endocrinology. 2009;150:3040–8.

40. Berge RK, Bjørndal B, Strand E, Bohov P, Lindquist C, Nordrehaug JE, et al. Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice. Lipids Health Dis. 2016;15:24.

41. Hovik R, Osmundsen H, Berge R, Aarsland A, Bergsæth S, Bremer J. Effects of thia-substituted fatty acids on mitochondrial and peroxisomal beta-oxidation. Studies in vivo and in vitro. Biochem J. 1990;270:167–73.

42. Lau SM, Brantley RK, Thorpe C. 4-Thia-trans-2-alkenoyl-CoA derivatives: properties and enzymatic reactions. Biochemistry. 1989;28:8255–62.

43. Gottlicher M, Demoz A, Svensson D, Tollef P, Berge RK, Gustafsson JA. Structural and metabolic requirements for activators of the peroxisome proliferator-activated receptor. Biochem Pharmacol. 1993;46:2177–84.

44. Strand E, Pedersen ER, Svingen GF, Olsen T, Bjørndal B, Karlsson T, et al. Serum Acylcarnitines and risk of cardiovascular death and acute myocardial infarction in patients with stable angina pectoris. J Am Heart Assoc. 2017;6(2). https://doi.org/10.1161/JAHA.116.003620.

45. Koves TR, Usher JR, Noland RC, Stentz D, Mosedale M, Ilkayeva O, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008;7:45–56.

46. van Vlies N, Ferdinandusse S, Turkenburg M, Wanders RJ, Vaz FM. PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochim Biophys Acta. 2007;1767:1134–42.

47. Burri L, Thoresen GH, Berge RK. The role of PPARalpha activation in liver and muscle. PPAR Res 2010;2010. https://doi.org/10.1155/2010/542359.

48. Wang Y, Mohtasham F, de las Heras J, Bacha F, Lee S, Chace DH, et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care. 2012;35:605–11.

49. Ha CY, Kim YJ, Paik JK, Kim OY, Paik YH, Lee EJ, et al. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol. 2012;76:674–82.

50. Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38:999–1007.